ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the ...
Abbott’s ABT structural heart line has received a major boost with the latest European regulatory approval for the company’s next-generation TriClip device. Per the company release, this ...
On Tuesday, February 13, 2024, the FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet regarding the premarket approval application (PMA) for Abbott Laboratories ...
The US Food and Drug Administration’s Circulatory System Devices Panel is set to decide the regulatory fate of the TriClip G4 (Abbott Medical) next week, and briefing documents released today suggest ...
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ -- The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., ...
Abbott won European approval for the latest generation of its TriClip system, the first transcatheter-based repair device designed to stem leaks in the heart's tricuspid valve. Separating the heart’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results